Michel Gillard
Fellow & Senior Director, CNS Biology at UCB Pharma
📍 Brussels Metropolitan Area, Belgium
Michel Gillard is a Fellow & Senior Director of CNS Biology at UCB Pharma, where he leads Neuroscience Discovery. His work focuses on in vitro pharmacology for CNS drug development, informed by his PhD from the Université libre de Bruxelles. He is a prolific author, particularly in the field of epilepsy research.
Michel played a pivotal role in identifying and characterizing the Synaptic Vesicle protein 2A (SV2A) as the molecular target for the successful antiepileptic drug levetiracetam.
Read the full overview →Experience
37 Years
Current Role
Fellow & Senior Director, CNS Biology
Job Level
Senior
Location
Brussels Metropolitan Area, Belgium
Personality Overview
Personality insights not availableWe need more social data to generate the DISC analysis and selling playbook. The professional details below are still available.
Priorities
Topics Michel cares about
Antiepileptic Drug Discovery
He has extensively published research on the discovery and mechanisms of antiepileptic drugs, including levetiracetam and brivaracetam.
CNS Target Validation
His research focuses on identifying and validating novel molecular targets within the central nervous system, such as the SV2A protein and orphan GPCRs like GPR17.
Career
Work history
1989
Fellow & Senior Director, CNS Biology
UCB Pharma
In the press
Media appearances
No media yetWe could not find public media appearances for this person.
Education
Education details unavailable
PhD
Education details unavailable
Université libre de Bruxelles
Social presence
Other UCB Pharma Employees
Explore more public profiles from related professionals.
More profiles
Discover additional public profiles from our index.
Search more profiles
Looking for someone else? Search here for anyone.